PD-1调控2型固有淋巴细胞在不同疾病中的研究进展  

Research progress of PD-1 regulating type 2 innate lymphocytes in different diseases

作　　者：刘春瑶 张登容 卜婷婷 罗镇颉 龙仙萍 汪松 LIU Chunyao;ZHANG Dengrong;BU Tingting;LUO Zhenjie;LONG Xianping;WANG Song(Emergency Department,Affiliated Hospital of Zunyi Medical University,Zunyi 563000,China;Department of Cardiology,Affiliated Hospital of Zunyi Medica l University,Zunyi 563000,China)

机构地区：[1]遵义医科大学附属医院急诊科,遵义563000 [2]遵义医科大学附属医院心内科,遵义563000

出　　处：《中国免疫学杂志》2025年第2期479-483,共5页Chinese Journal of Immunology

基　　金：国家自然科学基金项目(8216020197);贵州省科技厅联合基金项目(2017-7094)。

摘　　要：免疫失调在肿瘤、感染及过敏性疾病的发展中发挥重要作用。程序性死亡受体-1(PD-1)作为近年来备受关注的共抑制分子,可通过抑制2型固有淋巴细胞(ILC2s)的增殖及活化在各种免疫性疾病中参与免疫调节作用。ILC2s是新近发现的免疫细胞家族亚群,通过分泌2型细胞因子参与肿瘤免疫、抗寄生虫感染及组织损伤修复等。PD-1是其主要的免疫抑制分子,在不同免疫性疾病中可调控ILC2s发挥不同免疫调节作用。现就PD-1调控ILC2s在不同疾病中的作用及机制进行综述。Immune disorders play a vital role in the tumors,infections and allergic diseases.As a co-inhibitory molecule that has attracted much attention in recent years,programmed cell death protein 1(PD-1)can participate in immunomodulation in various immune diseases by inhibiting the proliferation and activation of type 2 innate lymphoid cells(ILC2s).ILC2s is a newly discovered subgroup of immune cell families,which is involved in tumor immunity,anti-parasitic infection and tissue damage repair by secreting type 2 cytokines.PD-1 is a major immunosuppressive molecule that can regulate the different immunomodulatory effects of ILC2s in different immune diseases.This article reviews the role and mechanism of PD-1 in regulating ILC2s in different diseases.

关 键 词：PD-1 ILC2s 细胞因子 免疫抑制 

分 类 号：R392.11[医药卫生—免疫学]